MTOR and invasive breast carcinoma: Furthermore, ZDHHC22 expression was negatively correlated with mTOR in tamoxifen-resistant BrCa cells, and restoring ZDHHC22 expression could improve the sensitivity of Tamoxifen-resistant strains in BrCa endocrine therapy.